Litcius/Paper detail

Serum CXCL10/IP-10 may be a potential biomarker for severe Mycoplasma pneumoniae pneumonia in children

Mengyao Li, Ying Chen, Huihan Li, Dehua Yang, Yunlian Zhou, Zhimin Chen, Yuanyuan Zhang

2021BMC Infectious Diseases23 citationsDOIOpen Access PDF

Abstract

BACKGROUND: How to early distinguish the severity of Mycoplasma pneumoniae pneumonia (MPP) is a worldwide concern in clinical practice. We therefore conducted this study to assess the relationship between levels of serum inflammatory chemokines and the severity of MPP. METHODS: In this prospective study, we enrolled 39 children with MPP, whose clinical information was collected, blood samples were assayed for cytokines and chemokines by ELISA. RESULTS: The levels of serum CXCL10 in children with severe MPP were significantly higher than those in children with mild MPP (2500.0 [1580.9-2500.0] vs. 675.7 [394.7-1134.9], P < 0.001). Measurement of CXCL10 levels in serum enabled the differentiation of children with severe MPP with an area under the curve (AUC) of 0.885 (95 % CI 0.779-0.991, P < 0.001), with a sensitivity of 81.0 % and a specificity of 83.3 %. CONCLUSIONS: Serum CXCL10 level may be a potential biomarker for severe MPP in children.

Topics & Concepts

BiomarkerCXCL10Mycoplasma pneumoniaeMedicinePneumoniaMedical microbiologyProspective cohort studyMycoplasma pneumoniaImmunologyChemokineMycoplasmaInternal medicineImmune systemBiologyMicrobiologyBiochemistryPneumonia and Respiratory InfectionsChemokine receptors and signalingRespiratory viral infections research